Compare SSL & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSL | BLCO |
|---|---|---|
| Founded | 1950 | 1853 |
| Country | South Africa | Canada |
| Employees | 27411 | N/A |
| Industry | Oil & Gas Production | Ophthalmic Goods |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.0B |
| IPO Year | N/A | 2022 |
| Metric | SSL | BLCO |
|---|---|---|
| Price | $12.71 | $15.48 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 12 |
| Target Price | N/A | ★ $18.55 |
| AVG Volume (30 Days) | ★ 2.9M | 380.7K |
| Earning Date | 04-17-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,101,000,000.00 |
| Revenue This Year | N/A | $8.63 |
| Revenue Next Year | $4.48 | $5.58 |
| P/E Ratio | $13.51 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $2.78 | $10.45 |
| 52 Week High | $13.02 | $18.92 |
| Indicator | SSL | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 78.11 | 34.23 |
| Support Level | $6.09 | $14.39 |
| Resistance Level | N/A | $17.66 |
| Average True Range (ATR) | 0.42 | 0.49 |
| MACD | 0.09 | -0.12 |
| Stochastic Oscillator | 91.55 | 1.16 |
Sasol Ltd operates as a vertically integrated chemicals and energy company through its two main businesses: the Southern Africa Energy & Chemicals business and the International Chemical business. It generates maximum revenue from the Southern Africa Energy & Chemicals business, which operates integrated value chains with feedstock sourced from the Mining and Gas operating segments. Geographically, the company generates the majority of its revenue from South Africa.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.